Morgan Stanley Initiates Coverage On AgomAb Therapeutics with Overweight Rating, Announces Price Target of $28

AgomAb Therapeutics NV ADR +5.07%

AgomAb Therapeutics NV ADR

AGMB

11.20

+5.07%

Morgan Stanley analyst Judah Frommer initiates coverage on AgomAb Therapeutics (NASDAQ: AGMB) with a Overweight rating and announces Price Target of $28.